Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (NCT03289299)
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.
Who can join: Review the eligibility criteria below.
Location: Moffitt Cancer Center — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Moffitt Cancer Center — Tampa, Florida
- University of Chicago Medical Center — Chicago, Illinois
- Indiana University Simon Cancer Center — Indianapolis, Indiana
- University of Kansas Cancer Center — Westwood, Kansas
- University of Maryland Medical Center — Baltimore, Maryland
- Mayo Clinic — Rochester, Minnesota
- Weill Cornell Medicine — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Swedish Cancer Institute — Seattle, Washington
- Medical College of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Smoldering Multiple Myeloma
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM — Boston, Massachusetts
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma — Rochester, New York
- Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial — Salt Lake City, Utah
- Screening for AL Amyloidosis in Smoldering Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Smoldering Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.